JNJ
JOHNSON & JOHNSON
NYSE: JNJ · New Brunswick, NJ · Healthcare
$226.16-4.53 (-1.96%)Closed
Market Cap$545.02B
Cash$20.10Bmost recent
Runwayprofitable
P/E (TTM)20.5EPS $11.03
52-Wk Range$142.39 – $248.56
Avg Volume8.5M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$226.16+60.9%
Pipeline

Drug candidates sponsored by JOHNSON & JOHNSON · ClinicalTrials.gov

85 drugs · 100 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 4Unnamed
Diaper Rash
Completed
2005-10past
1
Phase 4Bortezomib
Multiple Myeloma
Completed
2015-07past
1
Phase 4Listerine Clinical Solutions Teeth Strength
Healthy
Completed
2023-11-16past
1
Phase 3Placebo
Schizophrenia
Completed
2007-02past
2
Phase 3Paliperidone extended-release
Bipolar Disorder+1 more
Completed
2007-06past
1
Phase 3CG5503
Diabetic Neuropathy
Completed
2008-08past
1
Phase 3RISPERDAL CONSTA
Schizophrenia
Completed
2009-06past
1
Phase 2topiramate
Obesity+5 more
Completed
2010-03past
7
Phase 3Paliperidone ER
Affective Psychosis, Bipolar+3 more
Completed—2
Phase 3levofloxacin
Maxillary Sinusitis+2 more
Completed—2
Phase 3epoetin alfa
Anemia+5 more
Completed—4
Phase 3Topiramate; Placebo
Migraine+1 more
Completed—1
Phase 3galantamine
Alzheimer's Disease
Completed—1
Phase 2PROCRIT 40,000 IU QW
Peripheral Neuropathy, Chemotherapy-induced
Terminated
2008-08past
1
Phase 2Canagliflozin (JNJ-28431754)
Obesity+2 more
Completed
2011-04past
3
Phase 2JNJ-42160443
Osteoarthritis+5 more
Terminated
2011-06-30past
1
Phase 2Oxycodone CR (standard pain medication)
Osteoarthritis+4 more
Terminated
2011-07-01past
1
Phase 2Experimental Product 1% Colloidal Oatmeal Balm
Atopic Dermatitis
Completed
2016-04past
1
Phase 2ZARNESTRA, tipifarnib, R115777
Myelodysplastic Syndrome
Completed—1
Phase 2Unnamed
Type 2 Diabetes
Completed—1
Phase 2Trabectedin
Endometrial Neoplasms+2 more
Completed—1
Phase 2galantamine hydrobromide
Frontotemporal Dementia+1 more
Completed—1
Phase 1ULTRAM ER
Pain
Completed
2008-09past
1
Phase 1Paliperidone palmitate Treatment A
Schizophrenia
Completed
2009-06past
1
Phase 1JNJ-39393406
Healthy
Completed
2009-06past
1
Phase 1JNJ-31001074
Attention Deficit Hyperactivity Disorder+4 more
Completed
2009-12past
2
Phase 1Rabeprazole sodium: Treatment E
Healthy
Completed
2010-11past
1
Phase 1Treatment A: ORTHO EVRA patch (NGMN + EE) with an adhesive overlay
Healthy Volunteers
Completed
2011-07past
1
Phase 1[11C] JNJ-42491293
Healthy
Completed
2011-07past
1
Phase 1A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)
Healthy
Completed
2011-11past
1
Phase 1Cetirizine 10mg
Allergy
Completed
2019-02-03past
1
Phase 1JNJ-86974680
Carcinoma, Non-small-Cell Lung
Recruiting
2027-04-14
1
Phase 1JNJ-1761981
Neoplasms
Not yet recruiting
2028-01-12
1
Phase 1JNJ-87704916
Neoplasms
Recruiting
2028-11-08
1
Phase 1Doxorubicin
Soft Tissue Sarcoma+4 more
Completed—1
Phase 1ER OROS Paliperidone
Schizophrenia
Completed—1
Phase 1R306465
Neoplasms
Completed—1
Phase 1Drug combination/ 26489112
Healthy
Completed—1
N/AUnnamed
Common Infant Feeding Problems
Completed
1996-06past
1
N/AUnnamed
Gastrointestinal Problems
Completed
2007-03past
1
N/AUnnamed
Astigmatism
Completed
2008-02past
1
N/AUnnamed
Mineral Absorption in the Urine
Completed
2008-09past
1
N/AUnnamed
Myopia
Completed
2009-01past
1
N/AUnnamed
Premature Infants
Completed
2010-08past
1
N/AUnnamed
Dental Devices, Home Care
Completed
2010-10-29past
1
N/AUnnamed
Blister
Completed
2010-11past
1
N/AUnnamed
Myopia
Completed
2010-11-01past
1
N/AUnnamed
Pure Red-Cell Aplasia+1 more
Completed
2010-12past
1
N/AUnnamed
Respiratory Symptoms+2 more
Completed
2012-06past
1
N/AUnnamed
Presbyopia Correction
Completed
2014-08-01past
1
N/AUnnamed
Presbyopia
Completed
2014-11past
1
N/AUnnamed
Vision Correction
Completed
2015-09-01past
1
N/AMoisturizer A, F#9155-005
Skin+2 more
Completed
2016-03-25past
1
N/AUnnamed
Visual Acuity
Completed
2016-04-01past
1
N/AUnnamed
Refractive Error
Completed
2017-01-23past
1
N/AUnnamed
Visual Acuity
Completed
2017-05-04past
1
N/AUnnamed
Visual Acuity
Completed
2017-05-04past
1
N/AUnnamed
Fecal Microbiota
Completed
2017-07past
1
N/AUnnamed
Adult Skin Healthy Signs
Completed
2017-07-25past
1
N/AUnnamed
Acne Vulgaris
Completed
2017-09-06past
1
N/AUnnamed
Visual Acuity
Completed
2017-09-18past
1
N/AUnnamed
Visual Acuity
Completed
2017-10-02past
1
N/AUnnamed
Stress
Completed
2017-12-31past
1
N/AUnnamed
Growth
Withdrawn
2018-03past
1
N/AUnnamed
Dry Eye
Terminated
2019-01-28past
1
N/AUnnamed
Visual Acuity
Completed
2019-07-10past
1
N/AUnnamed
Community Health Workers
Completed
2019-07-26past
1
N/AUnnamed
Visual Acuity
Completed
2019-12-11past
1
N/AUnnamed
Newborns
Terminated
2020-06-04past
1
N/AUnnamed
Cataract+1 more
Completed
2020-06-18past
1
N/AUnnamed
Visual Acuity
Completed
2020-09-15past
1
N/AUnnamed
Visual Acuity
Completed
2021-11-29past
1
N/AUnnamed
Dermatitis, Atopic+3 more
Completed
2021-11-30past
1
N/AUnnamed
Common Cold+2 more
Completed
2022-01-20past
1
N/AUnnamed
Visual Acuity
Completed
2022-04-01past
1
N/AUnnamed
Ocular Physiology
Completed
2022-05-27past
1
N/AUnnamed
Cataract+1 more
Completed
2023-01-31past
1
N/AUnnamed
Thyroid Nodule
Completed
2023-09-28past
1
N/AUnnamed
Cataracts
Completed
2024-04-30past
1
N/AUnnamed
Visual Acuity
Completed
2024-05-22past
1
N/AUnnamed
Vision, Ocular
Completed
2024-06-12past
1
N/AUnnamed
Photodamaged Skin
Completed
2025-05-01past
1
N/AUnnamed
Cataracts
Completed
2025-05-20past
1
N/AUnnamed
Diabetes Mellitus, Type 2
Completed—1
N/AUnnamed
Cancer
Completed—1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

No peer cohort defined for JNJ. Cohorts currently cover gene editing, mRNA, rare-disease gene therapy, and large-cap biotech — more coming soon.